Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 7Phase 1 5Phase 1/2 3Phase 4 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoid Malignancies 1

Interventions

Saline Solution 6Fentanyl 6Sodium Chloride 5Letrozole 5Dexamethasone 5Pregabalin 4Ketamine 4Goserelin 4Gemcitabine 4Bevacizumab 4Tranexamic Acid 3Photochemotherapy 3Pemetrexed 3Paclitaxel 3Metformin 3Leuprolide 3Docetaxel 3Cyclophosphamide 3Carboplatin 3Capecitabine 3Acetaminophen 3ulipristal acetate 2sodium glycididazole 2nilotinib 2liposomal doxorubicin 2human papillomavirus vaccine, L1 type 16, 18 2flurbiprofen axetil 2fludarabine 2fluciclovine F-18 2epoetin beta 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Terminated × idelalisib × Clear all
NCT02739360 2020-03-04

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Gilead Sciences

Phase 4 Terminated
3 enrolled 5 charts

Lymphoid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡